Nagla Abdel Karim - University of Cincinnati

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 103 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Long-Term Survival by Number of Immune Checkpoint Inhibitors in PD-L1-Negative Metastatic NSCLC: A Systematic Review and Meta-Analysis

Ben Ponvilawan,Dhruv Bansal,Nagla Abdel Karim, Rahul Ramakrishnan,Janakiraman Subramanian

JAMA network openno. 2 (2025): e2457357-e2457357

Cited0Views0WOSBibtex

Pulmonary Neuroendocrine Neoplasms: the Molecular Landscape, Therapeutic Challenges, and Diagnosis and Management Strategies

Triparna Sen, Yosuke Dotsu, Virginia Corbett, Sonam Puri,Utsav Sen, Theresa A Boyle, Phil Mack, Fred Hirsch, Raid Aljumaily,Abdul Rafeh Naqash, Vineeth Sukrithan,Nagla Abdel Karim

The Lancet Oncologyno. 1 (2025): e13-e33

Cited0Views0WOSBibtex

Anaplastic Thyroid Carcinoma: Interplay of Predictive Factors, Treatment Challenges, and Survival Insights

Asad Ullah, Kavita Prasad,Asim Ahmed,Kue Tylor Lee,Abdul Qahar Khan Yasinzai, Asif Iqbal,Amir Humza Sohail, Dauod Arif, Sana Jogezai, Luis Brandi,Nabin Raj Karki,Marjan Khan,Agha Wali, Hritvik Jain,Nagla Abdel Karim

Expert review of endocrinology & metabolismno. 2 (2025): 129-138

Cited0Views0WOSBibtex

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients with SLFN11 Positive Extensive-Stage SCLC: S1929

Nagla Abdel Karim,Jieling Miao,Karen L Reckamp,Carl M Gay,Lauren A Byers, Ying-Qi Zhao,Mary W Redman,Daniel R Carrizosa,Wei-Lien Wang,William J Petty,Kathan Mehta,Bryan A Faller, Edem S Agamah,Samer S Kasbari, Rajini K Malisetti, Atul Kumar,John Schallenkamp, Krishna C Alluri,Jhanelle E Gray,Karen Kelly

Journal of thoracic oncology official publication of the International Association for the Study of Lung Cancerno. 3 (2024): 383-394

Cited0Views0WOSBibtex

Breaking Barriers: Patient-Derived Xenograft (PDX) Models in Lung Cancer Drug Development-Are We Close to the Finish Line

Nagla Abdel Karim, Mohamed Zaza,Janakiraman Subramanian

Translational lung cancer researchno. 8 (2024): 2098-2102

Cited0Views0WOSBibtex

Long-term Survival Outcomes of First-Line Immune Checkpoint Inhibitor in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer

Ben Ponvilawan,Dhruv Bansal,Nagla Abdel Karim,Janakiraman Subramanian

crossref（2024）

Cited0Views0Bibtex

State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs

Nagla Abdel Karim,Ahmed Magdy Rabea,Philip C. Mack,Janakiraman Subramanian,Ehab Khalil,Mai Sherif, Radwa Marawan, Tagrid Gaafar,Lobna Shash,Kei Suzuki,Manmeet Ahluwalia, Hisham Wahba, Salma Aboelela, Asrar Al Ahmadi,Hamed Al Husaini, Nada Mohsen,Rana Khaled,Neemat Kassem,Hussein Khaled, Noha El Said

JTO Clinical and Research Reportspp.100776, (2024)

Cited0Views0WOSBibtex

Phase II Randomized Study of Maintenance Atezolizumab (A) Versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer. S1929

Nagla Abdel Karim,Jieling Miao,Karen L. Reckamp,Carl M. Gay,Lauren A. Byers, Ying-Qi Zhao,Mary W. Redman,Daniel R. Carrizosa,Wei-Lien Wang,William J. Petty,Kathan Mehta,Bryan A. Faller, Edem S. Agamah,Samer S. Kasbari, Rajini K. Malisetti, Atul Kumar,John Schallenkamp, Krishna C. Alluri,Jhanelle E. Gray,Karen Kelly

Journal of Thoracic Oncology (2024)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn